Gm-Csf
Relapsed and Refractory
The First Affiliated Hospital of Xiamen UniversityPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Relapsed and Refractory cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Rivoceranib Zhengzhou University | Phase 4 | BB |
Glofitamab The First Affiliated Hospital of Xiamen University | Phase 2 | CCC |
cc-5013 The First Affiliated Hospital of Xiamen University | Phase 2 | CCC |
HUMANIZED, DUAL-AFFINITY RE-TARGETING, OR (DART), MOLECULE THAT RECOGNIZES BOTH CD123 AND CD3 City of Hope Medical Center | Phase 2 | CCC |
ca-4948 Curis, Inc. | Phase 1/2 | CCC |
View all 50 →
Same molecule, other indications
Gm-Csf is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →